Instead, 56% of nsSCLC-RB1−/TP53− harbored either canonical EGFR (39%) or KRAS (6%) mutations and/or displayed histologic components of NSCLC, most commonly in the form of adenocarcinoma (Fig. 6B). This evidence concerns the gene EGFR and non-small cell lung carcinoma.